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Retinopathy of prematurity (ROP) has an estimated global incidence 
of 20 000 infants per year.[1] South Africa (SA) has joined the ‘third 
epidemic’ of ROP, which is attributed to both increasing survival 
of premature infants and poor oxygen management in neonatal 
intensive care units (NICUs).[2] Oxygen management inadequacies 
in middle-income country NICUs lead to larger infants being at risk 
than in high-income countries.[3-5]
In SA, an estimated 16 000 infants are at risk of ROP and require 
screening each year.[2,6] In 1995, ROP accounted for 10.6% of cases of 
blindness in schools for the blind.[7] The prevalence of ROP among 
infants with birth weights (BWs) <1  500 g in tertiary hospitals in 
SA remains low (any ROP 16.3 - 24.5%, clinically significant ROP 
(CSROP) 1.56 - 4.4%[8-11] and sight-threatening ROP 0.6 - 2.9%[6]).
The first SA ROP guideline was published in 2013.[2] It recommends 
screening of infants with a gestational age (GA) of <32 weeks or a BW 
of <1 500 g, as well as larger infants (GA 32 - 35 weeks, BW 1 500 - 
2 000 g) with an increased risk of ROP.
The development of screening guidelines that are appropriate 
for all institutions in a middle-income country is challenging. 
ROP screening requirements are dependent on NICU quality of 
care, and this varies widely between units.[12-13] Screening infants 
of higher weight may not be feasible in units where resources are 
limited. Most secondary-level hospital NICUs in SA do not even 
have access to screening facilities.[2] In such NICUs, larger infants 
are likely to be at risk of ROP as a result of the level of care. In 
contrast, screening larger infants in SA tertiary institutions with 
high-quality neonatal care may represent inappropriate use of 
scarce resources. Ideally, ROP screening criteria should be based 
on local evidence.
Tygerberg Children’s Hospital (TCH), Western Cape Province, SA, 
reported a ROP prevalence of 31.1% (CSROP 7.1%) among preterm 
infants ventilated for respiratory distress (1986 - 1987).[14] Preterm 
infants treated exclusively with non-invasive ventilation in the first 
week of life (2009 - 2010) had a ROP prevalence of 21.8% (CSROP 
4.4%).[11] Only 1.5% of the latter cohort required treatment, and 
no infant with a BW >1 250 g had CSROP. The results from these 
subgroup analyses are instructive, but insufficient to inform local 
screening policy and resource allocation.
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Background. Screening guidelines for retinopathy of prematurity (ROP) used in high-income countries are not appropriate for middle-
income countries, and screening requirements may vary even between units within one city.
Objective. To determine optimal ROP screening criteria, and its workload implications, for Tygerberg Children’s Hospital (TCH), Cape 
Town, South Africa.
Methods. This cross-sectional study included premature infants screened for ROP at TCH from 1 January 2009 to 31 December 2014. 
Logistic regression analysis for prediction and classification was performed. Predictors were birth weight (BW) and gestational age (GA). 
Endpoints were clinically significant ROP (CSROP) and type 1 ROP (T1ROP).
Results. Of 1 104 eligible infants, 33.4% had ROP (CSROP 9.1%, T1ROP 2.5%). All T1ROP infants received laser therapy. The number of 
screening examinations was inversely correlated with GA and BW. The number needed to screen to identify one infant requiring treatment 
was 41 (entailing 83 examinations, 4 screening hours, one technician and three doctors). Screening infants with a GA of ≤28 weeks or a BW 
of <1 000 g would have detected all infants with T1ROP but missed two outliers with CSROP. These outliers would only have been detected 
with a GA of ≤32 weeks or a BW <1 500 g.
Conclusions. Detection of infants with T1ROP is resource intensive. Larger infants require screening to include a few outliers, but they 
require fewer examinations than smaller infants. Making local screening criteria narrower on the basis of a limited evidence base may be 
dangerous. Risk factors for CSROP in larger infants need to be researched.
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Objective
A focused analysis of the existing TCH ROP 
screening database was undertaken to deter-
mine optimal screening criteria for ROP at 
TCH and to explore the workload implications 
of using different BW and GA cut-off values.
Methods
This was a cross-sectional study, based on 
a database analysis, of infants born in the 
drainage area of TCH. Attending TCH 
neonatologists identified premature infants 
requiring ROP screening, and registered them 
in the ROP database. ROP screening activities 
at TCH commenced before the release of 
national screening criteria and were governed 
by local data and resources at the time. Infants 
were examined and staged according to the 
International Classification of ROP (2005 
revision)[15] by a trained ophthalmologist using 
a 28-dioptre condensing lens and an indirect 
ophthalmoscope. The screening team consisted 
of one technician and three doctors (the 
supervising paediatric ophthalmologist and 
two registrars in training). Retcam III imaging 
was performed in selected cases. Examination 
findings were recorded in hospital records 
and the database. Infants were examined from 
31 weeks corrected GA or 4 weeks after birth, 
whichever was later. Follow-up screens were 
performed 1 - 3-weekly until vascularisation 
of zone III was completed or the corrected GA 
of 41 weeks was reached. Infants with treatable 
stages of ROP (T1ROP) received laser therapy 
within 72 hours of diagnosis.
The sample size was fixed to the number 
of infants with information recorded in 
the database. Screening examinations with 
missing outcome data were excluded from 
the study. The recorded findings (zone, stage 
and presence of plus disease for each eye) 
were converted to binary outcome variables: 
any ROP, CSROP and T1ROP. CSROP was 
defined as ROP involving zone I, any stage 3 
ROP or plus disease associated with any 
stage ROP in any zone. T1ROP was defined 
as any stage zone I ROP with plus disease, 
zone I stage 3 with or without plus disease, or 
zone II stage 2 or 3 with plus disease.
ROP screening visit bookings,
n=2 643 for n=1 237 infants
Screening outcome not recorded, n=406 (15.4%) 
Infant was not brought for screening, n=187 (7.1%) 
Infant undilated or unstable, n=74 (2.8%) 
Unexplained, n=145 (5.5%) 
Recorded screening examination outcomes, n=2 237 for n=1 104 infants 
Female gender 
BW, median (IQR)  
GA, median (IQR)
Examinations, median (IQR)
Any ROP 
CSROP  
T1ROP
52.1% 
930 g (820 - 1 040)
28 weeks (27 - 29)
n=2 (1 - 3) 
33.4% (369/1 104)
9.1% (100/1 104)
2.5% (27/1 104) 
Examinations n=1 only
Not treated  
Median BW  
Median GA  
Treated 
Median BW  
Median GA  
Total
n=475 
n=1
N=476
980 g 
28 weeks 
- 
- 
Examinations n=2 - 3
Not treated  
Median BW  
Median GA  
Treated 
Median BW  
Median GA  
Total
n=470 
n=6
N=476
900 g 
28 weeks 
820 g 
28 weeks 
Not treated  
Median BW  
Median GA  
Treated 
Median BW  
Median GA  
Total
Not treated  
Median BW  
Median GA  
Treated 
Median BW  
Median GA  
Total
Examinations n=4 - 5 Examinations n=6 - 11
n=112
n=10
N=122
850 g 
28 weeks 
880 g 
28 weeks 
n=20 
n=10
N=30
785 g 
27 weeks 
767 g 
26 weeks 
Fig. 1. Overview of study population and outcomes.
Table 1. Numbers and proportions of infants developing ROP according to GA and 
BW group (N=621)
Total, N Any ROP, n (%) CSROP, n (%) T1ROP, n (%)
GA category (weeks)
24 - 25 15 8 (53.3) 4 (26.6) 2 (13.3)
26 - 27 221 77 (34.5) 28 (12.6) 7 (3.2)
28 - 29 292 88 (30.1) 20 (6.8) 5 (1.7)
30 - 32 79 14 (17.7) 3 (3.79) 0 (0.0)
33 - 37 14 4 (28.6) 1 (7.1) 0 (0.0)
Total 621 191 (30.8) 56 (9.0) 14 (2.3)
BW category (g)
<600 10 3 (30.0) 2 (20.0) 0 (0.0)
600 - 799 112 49 (43.8) 15 (13.4) 6 (5.4)
800 - 999 284 93 (32.7) 27 (9.5) 6 (2.1)
1 000 - 1 199 171 37 (21.6) 9 (5.3) 2 (1.2)
1 200 - 1 399 34 8 (23.5) 2 (5.9) 0 (0.0)
≥1 400 10 1 (10.0) 1 (10.0) 0 (0.0)
Total 621 191 (30.8) 56 (9.0) 14 (2.3)
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Data were entered in a custom-designed 
Microsoft Excel spreadsheet, and analysed using 
Stata 13 (StataCorp, USA). Ethical approval 
was obtained from the ethics committees of the 
University of Cape Town (Ref. No. 924/2014) 
and Stellenbosch University and Tygerberg 
Hospital (both Ref. No. S14/10/218).
Results
Between 1 March 2009 and 28 February 2014, 
1 104 infants were examined for ROP and 
the examination findings were recorded in 
the ROP database at TCH. Of the 2 643 ROP 
screening examinations (bookings) registered 
in the database, 406 examination findings 
(15.4%) were missing. Infants not arriving for 
scheduled examinations (7.1%) was the main 
reason for missing data (Fig. 1). Another 
explanation was inability to perform the 
examinations (2.8%) owing to poorly dilated 
pupils or clinical instability.
The median GA at birth was 28 weeks 
(interquartile range (IQR) 27 - 29, range 24 - 
37); 95% of infants had a GA of <32 weeks. 
The median BW was 930 g (IQR 820 - 1 040, 
range 523 - 2 600). Median GAs and BWs 
were similar across the 5 years of screening. 
The median postnatal age (PNA) of the 
infants at the first screening examination was 
5 weeks (IQR 4 - 7) and the postmenstrual 
age (PMA) was 33 weeks (IQR 32 - 35).
Retinopathy of prematurity
ROP (any ROP) was found in 33.4% of infants, 
CSROP in 9.1% and T1ROP in 2.5% (Fig. 1). 
The prevalence of ROP was highest in the 
subgroup of infants with a gestational age 
of <27 weeks (any ROP 44.9% (44/98) and 
CSROP 18.4% (18/98)). Overall, the median 
GA was 28 weeks in infants with any ROP and 
27 weeks in those with CSROP. The median 
BW was 865 g in infants with any ROP and 
826 g in those with CSROP. Rates of ROP 
according to GA and BW categories (among 
the subset of 621 infants with both GA and 
BW recorded in the database) are shown in 
Table 1. CSROP was detected in two infants 
with a GA >32 weeks or a BW >1 500 g. One 
of these infants had a BW of 866 g and a GA 
of 35 weeks. Stage 1 zone I ROP was detected 
in the right eye only, 4  weeks after birth. 
The other had a BW of 1 530 g and a GA of 
31 weeks. Pre-plus ROP was detected in zone II 
of the left eye at 34 weeks PMA (3 weeks PNA).
Screening cut-points
Among the 621 infants for whom both 
GA and BW were recorded, GA was signi-
ficantly associated with CSROP (odds ratio 
(OR) 0.710, 95% confidence interval (CI) 
0.579 - 0.872; p<0.001). The association 
between BW and CSROP was weaker 
(OR 0.998, 95% CI 0.996 - 0.9995; p=0.013). 
Both GA and BW were predictors of 
CSROP and T1ROP (Fig. 2). GA was not a 
significantly better predictor of CSROP than 
BW (p=0.521), and using both GA and BW 
in the prediction model was no better than 
using either GA (p=0.412) or BW (p=0.181). 
A GA cut-point of 30 weeks had a sensitivity 
of 97% and specificity of 9% in detecting 
CSROP. With this classification rule, two 
older infants (infant A: GA 35  weeks and 
BW 866 g; infant B: GA 31 weeks and 
BW 1 530 g) with CSROP would have been 
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Fig. 2. Receiver operating characteristic curves showing how prematurity predicts ROP.
Table 2. Workload implications and false negatives with application of different screening criteria (N=621) 
Screening criteria
A: All infants
B: GA ≤32 weeks 
or BW <1 500 g
C: GA ≤30 weeks 
or BW <1 200 g
D: GA ≤28 weeks 
or BW <1 000 g
Infants, N/n (%) 621 618 (99.5) 610 (98.2) 530 (85.4)
Examinations, N/n (%) 1 385 1 382 (99.8) 1 367 (98.7) 1 236 (89.2)
Examinations per infant, N/n (%) 2.23 2.24 (100.5) 2.24 (100.5) 2.33 (104.5)
Infants with CSROP, N/n (%) 56 56 (100.0) 55 (98.2) 54 (96.4)
Infants needed to screen to detect 1 infant with CSROP, N/n (%) 11 11 (100.0) 11 (100.0) 10 (90.9)
Examinations required to detect 1 infant with CSROP, N/n (%) 25 25 (100.0) 25 (100.0) 23 (92.0)
Infants with T1ROP 14 14 (100.0) 14 (100.0) 14 (100.0)
Infants needed to screen to detect one infant needing treatment, N/n (%) 44 44 (100.0) 44 (100.0) 38 (86.4)
Examinations required to detect one infant needing treatment, N/n (%) 99 99 (100.0) 97 (98.0) 88 (88.9)
CSROP missed (false negative), n - 0 1 2
T1ROP missed (false negative), n - 0 0 0
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missed in the given dataset, but neither 
required treatment.
A less sensitive cut-point of >28 weeks 
would have missed nine infants, one of whom 
would have required treatment. At a cut-point 
of 1 200 g, the BW classification rule had a 
sensitivity of 96% and a specificity of 6%. With 
this classification rule, three infants with a BW 
≥1 200 g and CSROP would have been missed, 
but none of them required treatment (infant 
B: GA 31 weeks and BW 1  530 g; infant C: 
GA 28 weeks and BW 1 200 g; infant D: GA 
28 weeks and BW 1 220 g). A less sensitive cut-
point of 1 000 g would have missed 12 infants 
(two with T1ROP). The last two rows of Table 
2 summarise infants missed (false negatives) 
when BW and GA cut-offs are combined and 
applied. Screening criteria D (GA ≤28  weeks or 
BW <1 000 g) would have detected all infants 
with CSROP requiring treatment (T1ROP). 
However, the most mature infant in the dataset 
with CSROP that did not require intervention 
had a GA of 31 weeks and BW of 1 530 g 
(infant B) and would have been detected with 
screening criteria B (GA ≤32  weeks or BW 
<1 500 g) only.
Infants needing treatment
Among the 1 104 infants with recorded 
screening examination out comes, all with 
T1ROP received laser therapy. The 27 infants 
treated for ROP were ≤29 weeks GA or 
≤1 060  g (median GA 27 weeks (IQR 26 - 28, 
range 24 - 29) and median BW 815 g (IQR 763 - 
940, range 640 - 1 060)). The median PMA of 
the infants at the time of T1ROP detection was 
35 weeks (IQR 33 - 38, range 31 - 43) and the 
PNA was 7 weeks (IQR 6 - 10, range 5 - 15). 
Fig. 3 reflects how infants needing treatment 
(T1ROP) changed over time, compared with 
those with CSROP and any ROP. Eleven of 
27 infants (40.7%) were treated during 2012. 
Any ROP and CSROP gradually increased 
over the study period from 13.9% to 48.3% and 
from 4.2% to 13.2%, respectively. T1ROP had 
a baseline of 1.8% with a peak in 2012 (11/234 
(4.7%) and returned to baseline in 2013.
Workload implications
The 1 104 infants required 2 237 screening 
examinations (Fig. 1). The median number 
of examinations per infant was two (IQR 1 - 
3, range 1 - 11), with 97.3% requiring fewer 
than six examinations. The median number 
of examinations for infants not needing 
treatment was two (IQR 1 - 3, range 1 - 10), 
as opposed to six (IQR 4 - 9, range 1 - 11) for 
treated infants. Thirteen infants (13/27, 48.1%) 
had reached the criterion for treatment at 
the first examination. However, the complete 
management of those treated involved four 
or more examinations in the majority of 
cases (20/27, 74.1%) (Fig. 1). The number 
needed to screen to identify one infant needing 
treatment was 41. Screening 41 infants entailed 
83 examinations (4 screening hours) by the 
screening team of one technician and three 
doctors (a paediatric ophthalmologist and two 
registrars in training).
The number of examinations required 
was inversely correlated with GA and BW 
(Spearman correlation coefficient –0.20 and 
–0.27; p<0.001). Table 2 shows the workload 
implications of applying different screening 
criteria (options B - D) to the subset of infants 
with both GA and BW recorded (option A). The 
narrower the screening criteria, the smaller the 
number of infants to be screened but also the 
higher the number of screening examinations 
per infant. The workload, expressed as the total 
number of examinations, therefore does not 
decrease in proportion to the number of infants 
screened. For example, the screening criteria 
in Table 2, option D, are GA ≤28 weeks or BW 
<1 000 g. Narrowing the screening criteria to 
option D would lead to a 14% reduction (6 fewer 
infants) in the number to be screened to detect 
one infant needing treatment, but only an 11% 
(not 14%) reduction (11 fewer examinations) in 
the number of examinations required to detect 
one needing treatment. Such a reduction in 
screening criteria would have decreased the 
workload by 91 fewer infants to be screened 
(149 fewer examinations) at the expense of 
missing 2 infants with CSROP.
Discussion
The prevalence of CSROP among infants with 
GAs <27 weeks at birth was 18.4% (18/98). 
Comparison with the ROP burden elsewhere 
is difficult because of the substantial variability 
in study designs, gestational ages of infants, 
survival rates and treatments used. Estimates of 
the prevalence of severe ROP from population-
based studies range from 5% to 35% in high-
income countries with equivalent NICUs.[16] 
The terms low-, middle- and high-income 
country do not always reflect on the quality of 
care in a particular country.[13] In countries such 
as SA, India and Brazil, the standard of care may 
vary widely between individual NICUs. Zin et 
al.[12] showed that in Rio de Janeiro the better 
NICUs were able to use narrower guidelines than 
other units in the same city.[12] The prevalence 
of T1ROP in this middle-income city ranged 
from 2.1% to 7.8% among NICUs.[12] The TCH 
T1ROP prevalence of 2.5% compares with the 
estimate at the lower end of the range, which 
was measured at the Rio de Janeiro federal 
government research institute.
As expected, the smaller and younger the 
infants, the higher the rates of ROP (Table 1). 
A significant number of infants >32 weeks and 
≥1  200 g were examined. This group included 
only infants at high risk for ROP as identified 
and referred for screening by neonatologists. 
This explains the higher than expected yield 
of ROP in this category. However, few of them 
had CSROP and none required treatment. One 
infant with CSROP had a BW of 1  530 g and 
another a GA of 35 weeks. However, when BW 
and GA are taken into account simultaneously, 
as in the SA national ROP screening guideline 
(GA ≤32 weeks or BW <1 500 g),[2] no infants 
with CSROP requiring follow-up fell outside 
the screening criteria. Neither of the two more 
mature infants mentioned reached the criteria 
for laser treatment. This indicates that neonatal 
care at TCH is well established and that narrower 
guidelines may be applicable for this specific unit.
T1ROP CSROP
Any ROP
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Fig. 3. Numbers of infants with ROP at TCH, 2009 - 2014.
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When planning ROP screening services, it must be kept in mind that 
it is the immature and sick infants that require the most work.[12] In 
this study the majority of more mature infants needed only one or 
two examinations. Including more mature infants in the screening 
programme does not increase the workload to the same extent as 
screening very immature infants.
Screening criteria D (GA ≤28 weeks or BW <1 000 g) would have 
detected all infants needing treatment. Screening criteria D plus referral 
of all infants at increased risk of ROP may have included the two more 
mature infants with outlying measurements. However, reducing GA and 
BW for inclusion in screening should be undertaken with caution owing 
to a relatively small evidence base. [13] Further investigation towards specific 
risk factors, or reasons for referral, is required in this cohort of infants. In 
addition, research is required to determine whether using this lower GA 
and BW plus a ‘sickness’ criterion (risk factors) would be an effective and 
efficient method of including the outliers. For example, prediction methods 
based on GA, BW and postnatal weight gain (WINROP, ROPScore and 
CHOP ROP) are employed to reduce ROP screening workload in high-
income settings. Poor generalisability limits their use.[15,17] Another tool has 
been developed by Binenbaum,[17] which can also be used in more mature 
infants at risk for ROP in countries with developing neonatal care systems 
(personal communication, Prof. C Gilbert, 10 February 2016). 
Accurate GA estimates are not routinely available in SA. GA in our 
study population was based on the date of the last normal menstruation, 
early ultrasound or the new Ballard score calculation at birth. BW was 
as good as GA in predicting CSROP, and using GA in addition to BW 
was not better at predicting CSROP. However, as was illustrated above 
with infant B in the dataset, using GA when it is available acts as a 
safety net to include those with high BW for GA (outliers).
Zin et al.[12] showed that NICUs with a <80% survival rate of infants 
with a BW <1 500 g should screen infants with a GA of ≤35 weeks or a 
BW of ≤1 500 g, and that NICUs with a survival rate of ≥80% could adopt 
narrower screening criteria of GA <32 weeks or BW ≤1  500 g.[12] The 
TCH survival rate of infants with a BW of <1 500 g gradually increased 
from 2009 to 2014 and was 89.7% on average during the study period 
(personal communication, Prof. J Smith, 29 July 2015). We also showed 
that screening infants with GA <32 weeks or a BW ≤1 500 g is appropriate 
in an NICU with a <1 500 g infant survival rate of >80%. In third-
epidemic settings, the infant mortality rate is therefore a useful proxy 
to indicate which infants should be examined. These findings need 
to be validated.
The Sweden ROP register (SWEDROP) showed that the incidence 
of severe ROP did not change substantially over time.[16] Increased 
survival balanced against improved neonatal intensive care can perhaps 
explain this. In our study, the numbers of infants seen increased over 
time and the screening programme became more efficient in detecting 
any ROP and CSROP over time. The prevalence of T1ROP was 2% 
each year across the study period, with the exception of a peak of 5% in 
2012. An increase of very immature infants at high risk for T1ROP plus 
the sudden increase in numbers of very low-birth-weight admissions 
(745 in 2012 and 801 in 2013, as opposed to 626 in 2011 and 632 in 
2010) can explain the peak. An improvement in overall neonatal care 
may explain the return to the norm in 2013.
Study limitations and research opportunities
Missing data limit the data analysis and interpretation in this study. 
The exact ROP screening programme coverage is not known, but our 
impression is that it is insufficient. Not all infants weighing <1  500  g 
were screened. Infants weighing ≥1  200 g were screened only if they 
had additional risk factors for ROP. A significant proportion (15.2%, 
405/2 670) of the examinations had missing outcomes and were exclu ded 
from analyses. Either GA or BW was not recorded for 43.8% (483/1 104) 
of infants, but thorough exploratory analyses revealed no clear pattern in 
missingness of data. Improved routine data collection is needed for audit 
purposes and to establish the ROP programme coverage.
Further studies are required to establish whether in resource-scarce 
environments more mature infants should be screened routinely, or 
whether screening more mature infants should rather be based on 
risk scores. Short- and long-term visual outcomes of infants are not 
recorded in the database. Study of these outcomes would guide scarce 
resource allocation. Digital imaging of the retina is employed in TCH 
ROP screening ward rounds, but its role in ROP screening workload 
reduction has yet to be established locally.
Conclusions
Unnecessary ROP screening examination should be avoided because 
it is resource intensive, requires specially trained ophthalmologists 
and is stressful for infants. Neonatal management is continually 
changing, so screening criteria should be revised accordingly. Local 
audit is an essential component that informs this revision. Local 
guidelines should ideally be based on prospective studies.
At TCH no infants needing treatment were larger than 1 060 g or older 
than 29 weeks, and no infant requiring follow-up for CSROP fell outside 
the current national screening criteria for GA (<32 weeks or BW <1 500 g). 
However, making the local screening criteria narrower on the basis of a 
limited evidence base may be dangerous. More mature infants require 
fewer screening examinations than immature infants. A modest broadening 
of current local inclusion criteria and screening infants of >32 weeks at 
increased risk of ROP should not result in an unmanageable workload. More 
research is required to develop screening criteria for the identification of 
more mature infants at risk of ROP in resource-limited settings.
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